Ovarian hyperstimulation syndrome: A new insight into an old enigma

Journal of the Society for Gynecologic Investigation

Volumn 5, Issue 3, 1998, Pages 110-113

  Orvieto, Raoul ^a,b   Ben Rafael, Zion ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cytokines; Interleukin 2; Intravenous immunoglobulin; OHSS; Pathophysiology; Vascular endothelial growth factor

Indexed keywords

CHORIONIC GONADOTROPIN; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

BLOOD LEVEL; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; OVARY DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0031863562     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(97)00113-5     Document Type: Review

References (36)

1. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome An update review . Obstet Gynecol Surv. 44:1989;430-440.
2. Polishuk W, Schenker J. Ovarian overstimulation syndrome. Fertil Steril. 20:1969;443-450.
3. Morris RS, Wong IL, Do YS, et al. The pathophysiology of ovarian hyperstimulation syndrome A proposal role of the ovarian derived prorenin to angiotensin cascade . Adv Exp Med Biol. 377:1995;391-398.
4. Navot D, Margalioth EJ, Laufer N, et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril. 48:1987;57-61.
5. Pride S, Yuen B, Moon Y. Clinical, endocrinologic and intraovarian prostaglandin responses to H1 receptor blockade in the ovarian hyperstimulation syndrome Studies in the rabbit model . Am J Obstet Gynecol. 148:1984;670-674.
6. Zaidse I, Friedman M, Lindembaum E, Askenazi R, Perez B, Paldi E. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 15:1983;55-60.
7. Leung P, Yuen B, Moon Y. Effect of prolactin in an experimental model of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 145:1983;847-849.
8. Schenker J, Polishuk W. The role of prostaglandins in the hyperstimulation syndrome. Obstet Gynecol. 66:1985;220-224.
9. Ben-Rafael Z, Orvieto R. Cytokines-involvement in reproduction. Fertil Steril. 58:1992;1093-1099.
10. McClure N, Healy DL, Rogers PAW, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236.
11. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid A hypothesis for an ovarian origin of the hyperstimulation syndrome . Fertil Steril. 63:1995;268-272.
12. Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells Importance in ovarian hyperstimulation syndrome . J Clin Endocrinol Metab. 80:1995;1967-1971.
13. Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo K-T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome A preliminary report . Fertil Steril. 65:1996;552-555.
14. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril. 67:1997;261-265.
15. Abramov Y, Schenker JG, Lewin A, Friedler S, Nisman B, Barak V. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod. 11:1996;1381-1386.
16. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril. 60:1993;826-833.
17. Loret de Mola JR, Flores JP, Baumgardner GP, Goldfarb JM, Gindlesperger V, Friedlander MA. Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome Ovarian immunohistochemical localization of interleukin-6 signal . Obstet Gynecol. 87:1996;581-587.
18. Loret de Mola JR, Baumgardner GP, Goldfarb JM, Friedlander MA. Ovarian hyperstimulation syndrome Pre-ovulatory serum concentration of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-α cannot predict its occurrence . Hum Reprod. 11:1996;1377-1380.
19. Revel A, Lavy Y, Antebi E, et al. Characterization of intraperitoneal factors involved in severe OHSS (abstract). Gynecol Endocrinol. 9:(Suppl):1995;FC70.
20. Revel A, Barak V, Lavy Y, et al. Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril. 66:1996;66-71.
21. Oppenheim JJ, Ruscetti FW, Faltynek C. Cytokines. Stites DP, Terr AI. Basic and clinical immunology. 7th ed. 1991;78-100 Appleton & Lange, East Norwalk, Connecticut.
22. Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z. Interleukin-2 and ovarian hyperstimulation syndrome A pilot study . Hum Reprod. 10:1995;24-27.
23. Orvieto R, Genazzani AR, Petraglia F, Schwartz A, Shelef M, Ben-Rafael Z. Interleukin-2 production by cultured human granulosa cells. Int J Fertil Menopausal Stud. 42:1997;297-300.
24. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin One possible mechanism of the clinical effect of intravenous immunoglobulin therapy . Immunol Rev. 139:1994;5-19.
25. Orvieto R, Achiron A, Margalit R, Ben-Rafael Z. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome. J Assist Reprod Genet (In press).
26. Wang LJ, Norman RJ. Concentrations of immunoreactive interleukin-1 and interleukin-2 in human preovulatory follicular fluid. Hum Reprod. 7:1992;147-150.
27. Barak V, Mordel N, Zajicek G, Kalichman I, Treves AJ, Laufer N. The correlation between interleukin-2 and soluble interleukin-2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in vitro fertilization patients. Hum Reprod. 7:1992;926-929.
28. Levy T, Orvieto R, Homburg R, Dekel A, Peleg D, Ben-Rafael Z. Severe ovarian hyperstimulation syndrome despite low plasma estrogen levels in hypogonadotropic hypogonadal patient. Hum Reprod. 11:1996;1177-1179.
29. Zalel Y, Orvieto R, Ben-Rafael Z, Homburg R, Fisher O, Insler V. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynaecol Endocrinol. 9:1995;313-315.
30. Friedman CI, Danforth DR, Herbosa-Encarnacion C, Arbogast L, Alak BM, Seifer DB. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertil Steril. 68:1997;607-612.
31. Yarali H, Fleige-Zahraka BG, Yuen BH, McComb PF. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril. 59:1993;657-661.
32. Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin YM, Elattar I. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol. 81:1993;108-111.
33. Fakih H, Bello S. Ovarian cyst aspiration A therapeutic approach to ovarian hyperstimulation syndrome . Fertil Steril. 58:1992;828-832.
34. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem. 271:1996;736-741.
35. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1 A potential mechanism for inflammatory angiogenesis . FEBS Lett. 372:1995;83-87.
36. Orvieto R, Ben-Rafael Z. The role of the immune system in severe ovarian hyperstimulation syndrome. Med Hypotheses. 45:1995;231-234.